Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zinc dibutyldithiocarbamate is a dithiocarbamate salt and the zinc salt of dibutyldithiocarbamic acid. It is primarily used as an ultra-fast accelerator in the vulcanization of natural and synthetic rubber and as a stabilizer in rubber-based adhesive systems. In addition to its industrial uses, it serves as an allergenic agent in epicutaneous patch tests for diagnosing allergic contact dermatitis (ACD) in individuals aged six years or older. The compound acts as a dermatological sensitizer and allergen by forming immunogenic protein–hapten complexes upon binding to skin proteins. It also has roles as an antifungal agrochemical and can cause allergic reactions or cytotoxicity under certain conditions[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc dibutyldithiocarbamate.